IL179905A0 - Piperazinediones as oxytocin receptor antagonists - Google Patents

Piperazinediones as oxytocin receptor antagonists

Info

Publication number
IL179905A0
IL179905A0 IL179905A IL17990506A IL179905A0 IL 179905 A0 IL179905 A0 IL 179905A0 IL 179905 A IL179905 A IL 179905A IL 17990506 A IL17990506 A IL 17990506A IL 179905 A0 IL179905 A0 IL 179905A0
Authority
IL
Israel
Prior art keywords
piperazinediones
receptor antagonists
oxytocin receptor
oxytocin
antagonists
Prior art date
Application number
IL179905A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32800053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL179905(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL179905A0 publication Critical patent/IL179905A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IL179905A 2004-06-23 2006-12-07 Piperazinediones as oxytocin receptor antagonists IL179905A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0414093.5A GB0414093D0 (en) 2004-06-23 2004-06-23 Novel compounds
PCT/EP2005/006760 WO2006000399A1 (en) 2004-06-23 2005-06-21 Novel compounds

Publications (1)

Publication Number Publication Date
IL179905A0 true IL179905A0 (en) 2007-05-15

Family

ID=32800053

Family Applications (2)

Application Number Title Priority Date Filing Date
IL179905A IL179905A0 (en) 2004-06-23 2006-12-07 Piperazinediones as oxytocin receptor antagonists
IL237513A IL237513A0 (en) 2004-06-23 2015-03-02 Piperazindiones as oxytocin receptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL237513A IL237513A0 (en) 2004-06-23 2015-03-02 Piperazindiones as oxytocin receptor antagonists

Country Status (30)

Country Link
US (9) US7550462B2 (enExample)
EP (2) EP1758886B1 (enExample)
JP (2) JP5405019B2 (enExample)
KR (1) KR101186447B1 (enExample)
CN (1) CN1972924B (enExample)
AR (1) AR049405A1 (enExample)
AU (1) AU2005256470B2 (enExample)
BR (1) BRPI0512376A (enExample)
CA (1) CA2571527C (enExample)
CY (1) CY1116183T1 (enExample)
DK (1) DK1758886T3 (enExample)
ES (1) ES2537801T3 (enExample)
GB (1) GB0414093D0 (enExample)
HK (1) HK1208669A1 (enExample)
HR (1) HRP20150401T1 (enExample)
HU (1) HUE025869T2 (enExample)
IL (2) IL179905A0 (enExample)
MA (1) MA28675B1 (enExample)
MX (1) MXPA06014545A (enExample)
MY (1) MY143578A (enExample)
NO (1) NO338769B1 (enExample)
NZ (1) NZ551733A (enExample)
PE (1) PE20060477A1 (enExample)
PL (1) PL1758886T3 (enExample)
PT (1) PT1758886E (enExample)
RU (1) RU2382038C2 (enExample)
SI (1) SI1758886T1 (enExample)
TW (1) TWI348466B (enExample)
WO (1) WO2006000399A1 (enExample)
ZA (1) ZA200610022B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
EP2392659B1 (en) 2002-06-17 2015-01-14 Thrasos Innovation, Inc. Single domain TDF-related compounds and analogs thereof
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
JP4971149B2 (ja) 2004-06-17 2012-07-11 スラソス セラピューティックス インコーポレーテッド Ｔｄｆ関連化合物およびその類似体
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
JP2009508532A (ja) 2005-09-20 2009-03-05 スラソス セラピューティックス インコーポレーテッド Ｔｄｆ関連化合物およびその類似体
EP2493874A1 (en) 2009-10-30 2012-09-05 Glaxo Group Limited Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl]-6- [(1s) - 1 -methylpropyl]-2,5- piperazinedione
EP4144351A1 (en) 2016-01-04 2023-03-08 ObsEva S.A. Hydroxypropylthiazolidine carboxamide derivatives as inhibitors of the prostaglandin f receptor
WO2017203012A1 (en) * 2016-05-27 2017-11-30 Glaxosmithkline Intellectual Property (No.2) Limited Epelsiban for use in the treatment of adenomyosis
BR112019001047A2 (pt) 2016-07-21 2019-04-30 ObsEva S.A. método para tratar um indivíduo submetido à terapia de transferência de embriões e kit
WO2019230647A1 (ja) * 2018-05-29 2019-12-05 花王株式会社 シートの快感情喚起性能の評価方法及び快感情喚起シート
CA3117323A1 (en) 2018-10-22 2020-04-30 William D. Carlson Therapeutic combinations of tdfrps and additional agents and methods of use
EP4025207A1 (en) 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP4103750A1 (en) 2020-02-10 2022-12-21 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) * 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
DE3830096A1 (de) 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
GB2326639A (en) 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
WO1999037304A1 (en) 1998-01-27 1999-07-29 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
CN1173946C (zh) 1998-01-29 2004-11-03 阿温蒂斯药物公司 制备n-[(脂族或芳族)羰基]-2-氨基乙酰胺化合物和环化化合物的方法
CA2289621A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (fbpase)
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0314738D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
SI1758886T1 (sl) 2015-06-30
US8742099B2 (en) 2014-06-03
GB0414093D0 (en) 2004-07-28
HUE025869T2 (en) 2016-05-30
CN1972924A (zh) 2007-05-30
IL237513A0 (en) 2015-04-30
EP1758886A1 (en) 2007-03-07
CY1116183T1 (el) 2017-02-08
KR20070031953A (ko) 2007-03-20
US7550462B2 (en) 2009-06-23
US20130253188A1 (en) 2013-09-26
JP5503709B2 (ja) 2014-05-28
MA28675B1 (fr) 2007-06-01
HK1208669A1 (en) 2016-03-11
PT1758886E (pt) 2015-04-22
US20100305127A1 (en) 2010-12-02
WO2006000399A1 (en) 2006-01-05
ES2537801T3 (es) 2015-06-12
US7919492B2 (en) 2011-04-05
AR049405A1 (es) 2006-07-26
EP2918580A1 (en) 2015-09-16
JP2013010790A (ja) 2013-01-17
EP1758886B1 (en) 2015-03-04
AU2005256470A1 (en) 2006-01-05
MY143578A (en) 2011-05-31
ZA200610022B (en) 2008-07-30
MXPA06014545A (es) 2007-03-12
KR101186447B1 (ko) 2012-09-27
JP2008503534A (ja) 2008-02-07
US20140235639A1 (en) 2014-08-21
CA2571527C (en) 2013-02-26
US20160030442A1 (en) 2016-02-04
TWI348466B (en) 2011-09-11
HRP20150401T1 (hr) 2015-05-08
US20070254888A1 (en) 2007-11-01
TW200616636A (en) 2006-06-01
US20120202811A1 (en) 2012-08-09
RU2382038C2 (ru) 2010-02-20
NO338769B1 (no) 2016-10-17
US20110152262A1 (en) 2011-06-23
NO20070173L (no) 2007-01-22
US9408851B2 (en) 2016-08-09
RU2007102274A (ru) 2008-07-27
NZ551733A (en) 2010-06-25
DK1758886T3 (da) 2015-04-27
HK1106499A1 (en) 2008-03-14
US20090247541A1 (en) 2009-10-01
PL1758886T3 (pl) 2015-08-31
US8202864B2 (en) 2012-06-19
JP5405019B2 (ja) 2014-02-05
CA2571527A1 (en) 2006-01-05
CN1972924B (zh) 2011-07-20
US20150157640A1 (en) 2015-06-11
BRPI0512376A (pt) 2008-03-11
PE20060477A1 (es) 2006-08-24
AU2005256470B2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
IL237513A0 (en) Piperazindiones as oxytocin receptor antagonists
TWI318206B (en) Histamine-3 receptor antagonists
IL182355A0 (en) Thrombin receptor antagonists
TWI346553B (en) Chemokine receptor antagonists
ZA200705002B (en) Substituted piperazines as CB1 antagonists
ZA200803811B (en) Neuropolin antagonists
IL182828A0 (en) Constrained compounds as cgrp-receptor antagonists
IL174538A0 (en) Thrombin receptor antagonists
IL190686A0 (en) Il-21 receptor antagonists
TWI341198B (en) Hydroisoindoline tachykinin receptor antagonists
TWI348467B (en) Nk1 antagonists
PL378023A1 (pl) Merkaptoimidazole jako związki antagonistyczne receptora CCR2
EP1812008A4 (en) ANTAGONISTS OF THE IL-8 RECEPTOR
ZA200904479B (en) Nitroderivatives as angiotensin II receptor antagonists
EP1874302A4 (en) ANTAGONISTS OF ANGIOTENSIN II RECEPTORS
IL178622A0 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
IL179888A0 (en) Compounds as ccr5 antagonists
ZA200802339B (en) Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
ZA200610121B (en) Substituted diketopiperazines as oxytocin antagonists
IL179518A0 (en) Mercaptoimidazoles as ccr2 receptor antagonists
ZA200703525B (en) Constrained compounds as CGRP-receptor antagonists
ZA200605574B (en) Hydroisoindoline tachykinin receptor antagonists
GB0525029D0 (en) Receptor Antagonist
SI1711465T1 (sl) Antagonisti hidroizoindolin tahikininskega receptorja
GB0409607D0 (en) Antagonist

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees